COMMUNIQUÉS West-GlobeNewswire

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
20/04/2026
Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File [...]
Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026
20/04/2026
Communiqué de presse Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026 20 avril 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de nanoprimer
20/04/2026
Une étude préclinique chez la souris a évalué le potentiel de la technologie nanoprimer à surmonter les barrières courantes rencontrées par les thérapies délivrées par nanoparticules lipidiques (« LNP »), qui sont [...]
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
20/04/2026
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, [...]
Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
20/04/2026
Press Release Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026 April 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an [...]
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
20/04/2026
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearance Pre-treatment with [...]
Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026
20/04/2026
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with [...]
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
20/04/2026
ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the [...]
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
20/04/2026
STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent [...]
Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026
19/04/2026
Company announcement – No. 7 / 2026 Zealand Pharma launches long-term incentive programs for Zealand Pharma’s Board of Directors, Corporate Management and employees for 2026 Copenhagen, Denmark, April 19, 2026 – Zealand [...]
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma
20/04/2026
KIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden, [...]
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
20/04/2026
Azetukalner data show significant reductions in seizure frequency across weekly, monthly and multi-year time points X-TOLE2 data featured in Late-breaking Science session show 53.2% reduction in monthly seizure [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
19/04/2026
Company announcement – No. 8 / 2026 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April [...]
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
19/04/2026
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
Fedora Pharmaceuticals Presentations at 2026 ESCMID Highlight Safety and Potent Bactericidal Activity of FPI-2119
19/04/2026
Potent antibacterial activity against Gram-negative community and hospital-acquired infections highlighted across eight posters and two presentationS EDMONTON, Alberta , April 19, 2026 (GLOBE NEWSWIRE) -- Fedora [...]
Herz P1 Smart Oximeter Claims Evaluated: Best Pulse Oxygen Monitor Device on the Market with Clinical-Grade Accuracy
19/04/2026
A 2026 informational report on the Herz P1 Smart Oximeter fingertip pulse oxygen monitor, covering the company's FDA 510(k) cleared positioning, ±2% SpO2 blood oxygen accuracy specifications, smart alarm alert features [...]
Vigor Boost Gummies Claims Evaluated: The ForceVital Male Enhancement Formula Under Investigation
18/04/2026
A 2026 informational overview of Vigor Boost Gummies ingredient disclosures, proprietary blend structure, label-vs-marketing discrepancies, ForceVital male enhancement positioning, and what men should verify before [...]
SlimLeaf Claims Evaluated: The FitBurn Formula Using Slim Leaf Ingredients for Weight Loss
18/04/2026
A 2026 informational report on the SlimLeaf Akkermansia probiotic gut health formula, FitBurn weight management ingredient research, Slim Leaf supplement facts, CFU dosing context, pricing, and what consumers should [...]
MAPS Welcomes Federal Action to Advance Science-Driven Psychedelic Research and Policy
18/04/2026
Federal action signals growing recognition of psychedelic therapies’ potential to address urgent mental health challenges, including PTSD, depression, and substance use disorders Expanding research must be paired with [...]

Pages